|Bid||35.59 x 3000|
|Ask||35.60 x 800|
|Day's Range||35.35 - 35.78|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||35.85|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||1.89 (5.35%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||48.67|
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.